Provenance
Written by SPS and the College of Sexual and Reproductive Health (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.
August 2025 – note the Faculty of Sexual and Reproductive Healthcare (FSRH) has now changed its name to the College of Sexual and Reproductive Healthcare (CoSRH). Some web pages and CoSRH documents will continue to display the FSRH name; where you see FSRH, this refers to CoSRH. All weblinks are still active.
Planned Review
Following the December 2025 launch of revised UKMEC guidelines from CoSRH, all reproductive health PGDs are being reviewed to ensure they reflect the updated UKMEC.
Updated versions will be published once approved through the SPS governance process, with an expected publication date of end January 2026.
PGD template attachment
The template PGD is attached below to download and use in conjunction with our implementation advice.
More reproductive health PGD templates
- Combined hormonal contraceptive vaginal ring
- Levonorgestrel 1500 microgram tablets for emergency contraception
- Progestogen only pill (POP) for contraception
- Ulipristal acetate 30mg tablets for emergency contraception
- Combined oral hormonal contraceptive (COC) in reproductive health
- Combined hormonal contraceptive transdermal patch
- Copper Intrauterine Device (Cu-IUD)
- Lidocaine 10mg/ml spray for IUD insertion or removal
- Lidocaine plus prilocaine cream for IUD insertion or removal
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
- Medroxyprogesterone acetate (SC-DMPA) injection for contraception
- Etonogestrel (e.g. Nexplanon®) implant for contraception
- Lidocaine injection for subdermal etonogestrel in contraception
All PGD templates
National PGD templates
Update history
- Planned review detail added
- Information added regarding name change of FSRH to CoSRH
- Updated version 2.3 added. Updated contraindications and cautions in line with Sayana Press® SPC. Reworded to align with the PGD for administration of DMPA via the subcutaneous route.
- Updated PGD template published - statement added regarding a suggested link between the prolonged use of medroxyprogesterone acetate and a small increased risk of intracranial meningioma in line with FSRH statement. Added exclusion of meningioma as per SPC.
- Version 2.1 published - minor updates to reflect updated FSRH guidance
- V1 removed as expiring 31/7/23
- Title, URL and summary amended.
- New V2.0 template added
- Published